Population-level health and economic impacts of introducing Vaccae vaccination in China: a modelling study.

ABSTRACT:

Introduction

Given the ageing epidemic of tuberculosis (TB), China is facing an unprecedented opportunity provided by the first clinically approved next-generation TB vaccine Vaccae, which demonstrated 54.7% efficacy for preventing reactivation from latent infection in a phase III trial. We aim to assess the population-level health and economic impacts of introducing Vaccae vaccination to inform policy-makers.

Methods

We evaluated a potential national Vaccae vaccination programme in China initiated in 2024, assuming 20 years of protection, 90% coverage and US$30/dose government contract price. An age-structured compartmental model was adapted to simulate three strategies: (1) no Vaccae; (2) mass vaccination among people aged 15-74 years and (3) targeted vaccination among old

SUBMITTER: Mao JJ 

PROVIDER: S-EPMC10254880 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature